Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus KERYDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus KERYDIN.
GRISEOFULVIN, ULTRAMICROSIZE vs KERYDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
None Documented
None Documented
9-24 hours (mean 15 hours); prolonged in liver disease.
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Category D/X
Category C
Antifungal
Antifungal